Negative regulators of JAK/STAT signaling in rheumatoid arthritis and osteoarthritis

International Journal of Molecular Sciences

Volumn 18, Issue 3, 2017, Pages

  Malemud, Charles J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Arthritis; Chondrocytes

Indexed keywords

CYTOKINE; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MIXED LINEAGE KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR OF ACTIVATED STAT; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BINDING;

APOPTOSIS; CELL DEATH; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCOMPETENT CELL; NONHUMAN; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SUPPRESSOR GENE; SYNOVIOCYTE; SYNOVIUM; TRANSCRIPTION INITIATION; TUNEL ASSAY; ANIMAL; CHONDROCYTE; DRUG EFFECTS; METABOLISM;

ANIMALS; APOPTOSIS; ARTHRITIS, RHEUMATOID; CHONDROCYTES; CYTOKINES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; JANUS KINASES; OSTEOARTHRITIS; PROTEIN BINDING; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85014098492     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18030484     Document Type: Review

References (72)

1. Miossec, P. An update on the cytokine network in rheumatoid arthritis. Curr. Opin. Rheumatol. 2004, 16, 218–222. [CrossRef] [PubMed]
2. Asquith, D.L.; McInnes, I.B. Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 2007, 19, 246–251. [CrossRef] [PubMed]
3. Thompson, C.; Davies, R.; Choy, E. Anti cytokine therapy in chronic inflammatory arthritis. Cytokine 2016, 86, 92–99. [CrossRef] [PubMed]
4. Mateen, S.; Zafar, A.; Moin, S.; Khan, A.Q.; Zubair, S. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin. Chim. Acta 2016, 455, 161–171. [CrossRef] [PubMed]
5. Upchurch, K.S.; Kay, J. Evolution of treatment from rheumatoid arthritis. Rheumatology 2012, 6, vi28–vi36.
6. Malemud, C.J. The biological basis of osteoarthritis: State of the evidence. Curr. Opin. Rheumatol. 2015, 27, 289–294. [CrossRef] [PubMed]
7. Calich, A.L.; Domiciano, D.S.; Fuller, R. Osteoarthritis: Can anti-cytokine therapy play a role in treatment? Clin. Rheumatol. 2010, 29, 451–455. [CrossRef] [PubMed]
8. Malemud, C.J.; Islam, N.; Haqqi, T.M. Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies. Cells Tissues Organs 2003, 174, 34–38. [CrossRef] [PubMed]
9. Leonard, W.J.; O’Shea, J.J. JAKS and STATs: Biological implications. Annu. Rev. Immunol. 1998, 16, 293–322. [CrossRef] [PubMed]
10. Decker, T.; Kovarik, P. Serine phosphorylation of STATs. Oncogene 2000, 19, 2628–2637. [CrossRef] [PubMed]
11. Turkson, J.; Jove, R. STAT proteins: Novel molecular targets for cancer drug discovery. Oncogene 2000, 19, 6613–6626. [CrossRef] [PubMed]
12. Malemud, C.J.; Pearlman, E. Targeting JAK/STAT signaling pathway in inflammatory diseases. Curr. Signal Transduct. Ther. 2009, 4, 201–221. [CrossRef]
13. Kaplan, M.H. STAT4: A critical regulator of inflammation in vivo. Immunol. Res. 2005, 31, 231–242. [CrossRef]
14. El Kasmi, K.C.; Holst, J.; Coffre, M.; Mielke, L.; DePauw, A.; Lhocine, N.; Smith, A.M.; Rutschman, R.; Kaushal, D.; Shen, Y.; et al. General nature of STAT3-activated anti-inflammatory response. J. Immunol. 2006, 177, 7880–7888. [CrossRef] [PubMed]
15. Ivashkiv, L.B.; Hu, X. Signaling by STATs. Arthritis Res. Ther. 2004, 6, 159–168. [CrossRef] [PubMed]
16. DiPlacido, L.D.; Craft, J. Emerging from the shadows: Follicular helper T cells in autoimmunity. Arthritis Rheumatol. 2010, 62, 6–8. [CrossRef] [PubMed]
17. Yamaoka, K. Janus kinase inhibitors for rheumatoid arthritis. Curr. Opin. Chem. Biol. 2016, 32, 29–33. [CrossRef] [PubMed]
18. Malemud, C.J. Dysfunctional immune-mediated inflammation in rheumatoid arthritis dictates that development of anti-rheumatic disease drugs target multiple intracellular signaling pathways. Antiinflamm. Antiallergy Agents Med. Chem. 2011, 10, 78–84. [CrossRef] [PubMed]
19. McInnes, I.B.; Buckley, C.D.; Isaacs, J.D. Cytokines in rheumatoid arthritis—Shaping the immunological landscape. Nat. Rev. Rheumatol. 2016, 12, 63–68. [CrossRef] [PubMed]
20. Stark, G.R.; Darnell, J.E., Jr. The JAK-STAT pathway at 20. Immunity 2012, 36, 503–514. [CrossRef] [PubMed]
21. Malemud, C.J. Inhibitors of stress-activated/mitogen-activated protein kinase pathways. Curr. Opin. Pharmacol. 2007, 7, 339–343. [CrossRef] [PubMed]
22. Malemud, C.J. Targeted drug development for arthritis. Future Med. Chem. 2012, 4, 701–703. [CrossRef] [PubMed]
23. MacFarlane, L.A.; Todd, D.J. Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis. Int. J. Rheum. Dis. 2014, 17, 359–368. [CrossRef] [PubMed]
24. Aittomäki, S.; Pesu, M. Therapeutic targeting of the Jak/STAT pathway. Basic Clin. Pharmacol. Toxicol. 2014, 114, 18–23. [CrossRef] [PubMed]
25. Vijayakrishnan, L.; Venkataramanan, R.; Gulati, P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol. Sci. 2011, 32, 25–34. [CrossRef] [PubMed]
26. Mesa, A. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs 2010, 13, 394–403. [PubMed]
27. Tam, C.S.; Verstovsek, S. Investigational Janus kinase inhibitors. Expert Opin. Investig. Drugs 2013, 22, 687–699. [CrossRef] [PubMed]
28. Malemud, C.J. The small molecular weight inhibitor of protein kinase revolution for the treatment of rheumatoid arthritis. In Drug Discovery and Development—From Molecules to Medicine; Vallisuta, O., Olimat, S., Eds.; InTech Publishing: Rijeka, Croatia, 2015; pp. 163–179.
29. Malemud, C.J.; Blumenthal, D.E. Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/Clinical perspectives. World J. Orthop. 2014, 5, 496–503. [CrossRef] [PubMed]
30. Malemud, C.J. Suppressor of cytokine signaling and rheumatoid arthritis. Integr. Mol. Med. 2016, 3, 17–20.
31. Shuai, K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res. 2006, 16, 196–202. [CrossRef] [PubMed]
32. Greenhalgh, C.J.; Hilton, D.J. Negative regulation of cytokine signaling. J. Leukoc. Biol. 2001, 70, 348–356. [PubMed]
33. Yoshimura, A.; Nishinakamura, H.; Matsumura, Y.; Hanada, T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res. Ther. 2005, 7, 100–110. [CrossRef] [PubMed]
34. Yin, Y.; Liu, W.; Dai, Y. SOCS3 and its role in associated diseases. Hum. Immunol. 2015, 76, 775–780. [CrossRef] [PubMed]
35. Derenzini, E.; Younes, A. Targeting the JAK-STAT pathway in lymphoma: A focus on pacritinib. Expert Opin. Investig. Drugs 2013, 22, 775–785. [CrossRef] [PubMed]
36. Rani, A.; Murphy, J.J. STAT5 in cancer and immunity. J. Interf. Cytokine Res. 2016, 36, 226–237. [CrossRef] [PubMed]
37. Furgan, M.; Akinleye, A.; Mukhi, N.; Mittal, V.; Chen, Y.; Liu, D. STAT inhibitors for cancer therapy. J. Hematol. Oncol. 2013, 6, 90. [CrossRef] [PubMed]
38. Herbein, G.; Gras, G.; Khan, K.A.; Abbas, W. Macrophage signaling in HIV-1 infection. Retrovirology 2010, 7, 34. [CrossRef] [PubMed]
39. Kershaw, N.J.; Murphy, J.M.; Liau, N.P.; Varghese, L.N.; Laktyushin, A.; Whitlock, E.L.; Lucet, I.S.; Nicola, N.A.; Babon, J.J. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 2013, 20, 469–476. [CrossRef] [PubMed]
40. Giordanetto, F.; Kroemer, R.T. A three-dimensional model of Suppressor of Cytokine Signaling-1 (SOCS-1). Protein Eng. 2003, 16, 115–124. [CrossRef] [PubMed]
41. De Souza, D.; Fabri, L.J.; Nash, A.; Hilton, D.J.; Nicola, N.A.; Baca, M. SH2 domains from suppressor of cytokine signaling-3 and protein phosphatase SHP-2 have similar binding specificities. Biochemistry 2002, 41, 9229–9236. [CrossRef] [PubMed]
42. Firestein, G.S. Immunological mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 2005, 11 (Suppl. 3), S39–S44. [CrossRef]
43. Astry, B.; Harberts, E.; Moudgil, K.D. A cytokine-centric view of the pathogenesis and treatment of rheumatoid arthritis. J. Interf. Cytokine Res. 2011, 31, 927–940. [CrossRef] [PubMed]
44. Peng, S.L. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology 2006, 45, 26–30. [CrossRef] [PubMed]
45. Choe, J.Y.; Park, K.Y.; Park, S.H.; Lee, S.I.; Kim, S.K. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Arthritis Res. Ther. 2013, 15, R26. [CrossRef] [PubMed]
46. Świerkot, J.; Nowak, B.; Czarny, A.; Zaczyńska, E.; Sokolik, R.; Madej, M.; Korman, L.; Sebastian, A.; Wojtala, P.; Lubiński, L.; et al. The activity of JAK/STAT and NF-κB in patients with rheumatoid arthritis. Adv. Clin. Exp. Med. 2016, 25, 709–717. [CrossRef] [PubMed]
47. Shouda, T.; Yoshida, T.; Hanada, T.; Wakioka, T.; Oishi, M.; Miyoshi, K.; Komiya, S.; Kosai, K.; Hanakawa, Y.; Hashimoto, K.; et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Investig. 2001, 108, 1781–1788. [CrossRef] [PubMed]
48. Mahony, R.; Ahmed, S.; Diskin, C.; Stevenson, N.J. SOCS3 revisited: A broad regulator of disease, now ready for therapeutic use? Cell. Mol. Life Sci. 2016, 73, 3323–3336. [CrossRef] [PubMed]
49. Malemud, C.J.; Schulte, M.E. Is there a final common pathway for arthritis? Future Rheumatol. 2008, 3, 253–268. [CrossRef]
50. Lim, H.; Kim, H.P. Matrix metalloproteinase-13 expression in IL-1β-treated chondrocytes by activation of the p38 MAPK/c-Fos/AP-1 and JAK/STAT pathways. Arch. Pharm. Res. 2011, 34, 109–117. [CrossRef] [PubMed]
51. Islam, S.; Kermode, T.; Sultana, D.; Moskowitz, R.W.; Mukhtar, H.; Malemud, C.J.; Goldberg, V.M.; Haqqi, T.M. Expression profile of protein tyrosine kinase genes in human osteoarthritis chondrocytes. Osteoarthr. Cartil. 2001, 9, 684–693. [CrossRef] [PubMed]
52. De Andrés, M.C.; Imagawa, K.; Hashimoto, K.; Gonzalez, A.; Goldring, M.B.; Goldring, M.B.; Roach, H.I.; Oreffo, R.O. Suppressors of cytokine signalling (SOCS) are reduced in osteoarthritis. Biochem. Biophys. Res. Commun. 2011, 407, 54–59. [CrossRef] [PubMed]
53. Lao, M.; Shi, M.; Zou, Y.; Huang, M.; Ye, Y.; Qiu, Q.; Xiao, Y.; Zeng, S.; Liang, L.; Yang, X.; et al. Protein inhibitor of activated STAT3 regulates migration, invasion, and activation of fibroblast-like synoviocytes in rheumatoid arthritis. J. Immunol. 2016, 196, 596–606. [CrossRef] [PubMed]
54. Hikisz, P.; Kiliańska, Z.M. PUMA, a critical mediator of cell death—One decade on from its discovery. Cell. Mol. Biol. Lett. 2012, 17, 646–669. [CrossRef] [PubMed]
55. Park, S.M.; Yoon, J.B.; Lee, T.H. Receptor-interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro. FEBS Lett. 2001, 566, 151–156. [CrossRef] [PubMed]
56. O’Donnell, M.A.; Ting, A.T. NFκB and ubquitination: Partners in disarming RIPK1-mediated cell death. Immunol. Res. 2012, 54, 214–226. [CrossRef] [PubMed]
57. Newton, K. RIPK1 and RIPK3: Critical regulators of inflammation and cell death. Trends Cell Biol. 2015, 25, 347–353. [CrossRef] [PubMed]
58. Silke, J.; Rickard, J.A.; Gerlic, M. The diverse role of RIP kinases in necropotosis and inflammation. Nat. Immunol. 2015, 16, 689–697. [CrossRef] [PubMed]
59. Feoktistova, M.; Leverkus, M. Programmed necrosis and necroptosis signalling. FEBS J. 2015, 282, 19–31. [CrossRef] [PubMed]
60. Rodriguez, D.A.; Weinlich, R.; Brown, S.; Guy, C.; Fitzgerald, P.; Dillon, C.P.; Oberst, A.; Quarato, G.; Low, J.; Cripps, J.G.; et al. Characterization of the RIPK3-mediated phosphorylation of the activation loop of MLML during necroptosis. Cell Death Differ. 2016, 23, 76–88. [CrossRef] [PubMed]
61. Ikeda, F. Linear ubiquitination signals in adaptive immune responses. Immunol. Rev. 2015, 266, 222–236. [CrossRef] [PubMed]
62. Lewis, A.C.; Malemud, C.J. Correction of dysfunctional apoptosis in arthritis by pharmacologic interventions: Focus on altering the activity of inhibitor of apoptosis protein. In Recent Research Developments in Pharmacology; Pandalai, S.G., Ed.; Research Signpost: Kerala, India, 2011; pp. 69–84.
63. Abhari, B.A.; Davoodi, J. A mechanistic insight into SMAC peptide interference with XIAP-Bir2 inhibition of executioner caspases. J. Mol. Biol. 2008, 381, 645–654. [CrossRef] [PubMed]
64. Verhagen, A.M.; Ekert, P.G.; Pakusch, M.; Silke, J.; Connolly, Y.; Reid, G.E.; Moritz, R.L.; Simpson, R.J.; Vaux, D.L.; et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102, 43–53. [CrossRef]
65. Dharmapatni, A.A.; Smith, M.D.; Findlay, D.M.; Holding, C.A.; Evdokiou, A.; Ahern, M.J.; Weedon, H.; Chen, P.; Screaton, G.; Xu, X.N.; et al. Elevated expression of caspase-3 inhibitors, survivin, and xIAP correlates with low levels of apoptosis in active rheumatoid arthritis. Arthritis Res. Ther. 2009, 11, R13. [CrossRef] [PubMed]
66. Dharmapatni, A.A.; Cantley, M.D.; Marino, V.; Perilli, E.; Crotti, T.N.; Smith, M.D.; Haynes, D.R. The X-linked inhibitor of apoptosis protein inhibitor embelin suppresses inflammation and bone erosion in collagen-antibody-induced arthritis mice. Mediat. Inflamm. 2015, 2015, 564042. [CrossRef] [PubMed]
67. Lawlor, K.E.; Khan, N.; Mildenhall, A.; Gerlic, M.; Croker, B.A.; D’Cruz, A.A.; Hall, C.; Kaur, S.S.; Anderton, H.; Masters, S.L.; et al. RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. Nat. Commun. 2015, 6, 6282. [CrossRef] [PubMed]
68. Yabal, M.; Müller, N.; Adler, H.; Knies, N.; Groß, C.J.; Damgaard, R.B.; Kanegane, H.; Ringelhan, M.; Kaufmann, T.; Heikenwälder, M.; et al. XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell Rep. 2014, 7, 1796–1808. [CrossRef] [PubMed]
69. Liu, Y.; Zhang, D.T.; Liu, X.G. mTOR signaling in T cell immunity and autoimmunity. Int. Rev. Immunol. 2015, 34, 50–66. [CrossRef] [PubMed]
70. Winsauer, G.; Resch, U.; Hofer-Warbinek, R.; Schichi, Y.M.; de Martin, R. XIAP regulates bi-phasic NF-κB induction involving physical interaction and ubiquitination of MEKK2. Cell Signal. 2008, 20, 2107–2112. [CrossRef] [PubMed]
71. De Almagro, M.C.; Vucic, D. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp. Oncol. 2012, 34, 200–211. [PubMed]
72. Malemud, C.J. Chondrocyte apoptosis in rheumatoid arthritis: Is preventive therapy possible? Immunotherapy 2015, 1, 102. [CrossRef] [PubMed]